Source comparison
ARA-290 vs Erythropoietin and Related Tissue-Protective Peptides
Because ARA-290 is defined largely by what it is not (erythropoietic), a side-by-side comparison with its parent molecule and with the broader helix-B peptide family clarifies where it sits. The table below summarizes distinctions drawn from the research liter
This comparison does not assign a generated winner or score.
- Because ARA-290 is defined largely by what it is not (erythropoietic), a side-by-side comparison with its parent molecule and with the broader helix-B peptide family clarifies where it sits. The table below summarizes distinctions drawn from the research literature.
- Molecular class
- ~165-residue glycoprotein hormone
- 11-amino acid linear peptide
- Primary receptor
- EPOR homodimer (plus IRR)
- Innate repair receptor (EPOR–CD131) selectively
- Raises red cell count / hematocrit
- Yes (its approved use)
- No — non-erythropoietic in models[1]
- Thrombosis / platelet activation risk
- Documented concern at tissue-protective doses
- Not observed in the same way in reported studies[2]
- Plasma half-life
- Hours
- Very short (~2 minutes)[2]
- Regulatory status
- FDA-approved for specific anemias
- Investigational; not approved for any indication
- The half-life comparison in that table points to one of the more intriguing puzzles in the field, discussed next: ARA-290 disappears from plasma within minutes, yet the biological effects attributed to it in animal models persist for days. A 2015 review framed this as “long-lasting effects of a short-lived peptide,” proposing that the peptide flips a self-sustaining cellular program rather than needing to occupy its receptor continuously.[2] Whether this “molecular switch” framing fully holds remains an open scientific question.
- Within this library, the cardiovascular bioregulator context is explored further in our Cardiogen research overview; while Cardiogen is a peptide bioregulator of a different lineage, both illustrate the recurring interest in molecules that might protect vascular and cardiac tissue under stress. Researchers comparing candidates in this space should treat each on its own evidence rather than assuming class-wide effects.